Cargando…

Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study

INTRODUCTION: Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide. In addition, TBI may cause paroxysmal sympathetic hyperactivity (PSH), which is associated with poor clinical outcomes. This study aimed to evaluate the safety and effectiveness of clonidine in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshaya, Abdulrahman I, Aldhaeefi, Mohammed, Alodhaiyan, Nada, Alqahtani, Maha, Althewaibi, Sarah, Alshahrani, Wala, Al Sulaiman, Khalid, Al Harbi, Shmeylan A., Vishwakarma, Ramesh, Aldabbagh, Tariq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631352/
https://www.ncbi.nlm.nih.gov/pubmed/37933150
http://dx.doi.org/10.1177/00368504231201298
_version_ 1785132356744511488
author Alshaya, Abdulrahman I
Aldhaeefi, Mohammed
Alodhaiyan, Nada
Alqahtani, Maha
Althewaibi, Sarah
Alshahrani, Wala
Al Sulaiman, Khalid
Al Harbi, Shmeylan A.
Vishwakarma, Ramesh
Aldabbagh, Tariq
author_facet Alshaya, Abdulrahman I
Aldhaeefi, Mohammed
Alodhaiyan, Nada
Alqahtani, Maha
Althewaibi, Sarah
Alshahrani, Wala
Al Sulaiman, Khalid
Al Harbi, Shmeylan A.
Vishwakarma, Ramesh
Aldabbagh, Tariq
author_sort Alshaya, Abdulrahman I
collection PubMed
description INTRODUCTION: Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide. In addition, TBI may cause paroxysmal sympathetic hyperactivity (PSH), which is associated with poor clinical outcomes. This study aimed to evaluate the safety and effectiveness of clonidine in patients with TBI and suspected PSH. METHODS: A retrospective cohort study for critically ill patients with TBI with suspected PSH admitted to intensive care units (ICUs) from 1 May 2016 to 31 January 2020 at a tertiary academic medical center. Eligible patients were categorized based on clonidine use during their ICU stay (Clonidine group vs. Control group). The primary outcome was the improvement in functional outcomes during ICU stay, defined by a delta Glasgow Coma Score (GCS). Secondary outcomes included ICU and hospital length of stay, heart rate variation, and 90-day mortality. RESULTS: A total of 2915 patients were screened, of which 169 were included. Based on multiple regression analysis, patients who received clonidine showed better improvement in functional outcomes by a higher mean delta GCS than patients who did not (Beta Coeff. 0.41; CI: 0.07 – 0.74; P = 0.02). In addition, the patient's GCS upon ICU discharge and IV opioids requirement on day three were higher in the clonidine group than control (beta coefficient (95% CI): 0.18 (0.03, 0.32); p = 0.02 and beta coefficient (95% CI): 1.38 (0.24, 2.52); p = 0.02, respectively). No statistical differences were observed in any of the other secondary outcomes after adjusting for confounders. CONCLUSION: This study found that patients who received clonidine had better functional outcomes during their ICU stay, as shown by their delta GCS than those who did not. Other outcomes were similar between the groups. More data are needed to explore the role of clonidine in patients with TBI with suspected PSH.
format Online
Article
Text
id pubmed-10631352
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-106313522023-11-07 Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study Alshaya, Abdulrahman I Aldhaeefi, Mohammed Alodhaiyan, Nada Alqahtani, Maha Althewaibi, Sarah Alshahrani, Wala Al Sulaiman, Khalid Al Harbi, Shmeylan A. Vishwakarma, Ramesh Aldabbagh, Tariq Sci Prog Medicine & Health Sciences INTRODUCTION: Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide. In addition, TBI may cause paroxysmal sympathetic hyperactivity (PSH), which is associated with poor clinical outcomes. This study aimed to evaluate the safety and effectiveness of clonidine in patients with TBI and suspected PSH. METHODS: A retrospective cohort study for critically ill patients with TBI with suspected PSH admitted to intensive care units (ICUs) from 1 May 2016 to 31 January 2020 at a tertiary academic medical center. Eligible patients were categorized based on clonidine use during their ICU stay (Clonidine group vs. Control group). The primary outcome was the improvement in functional outcomes during ICU stay, defined by a delta Glasgow Coma Score (GCS). Secondary outcomes included ICU and hospital length of stay, heart rate variation, and 90-day mortality. RESULTS: A total of 2915 patients were screened, of which 169 were included. Based on multiple regression analysis, patients who received clonidine showed better improvement in functional outcomes by a higher mean delta GCS than patients who did not (Beta Coeff. 0.41; CI: 0.07 – 0.74; P = 0.02). In addition, the patient's GCS upon ICU discharge and IV opioids requirement on day three were higher in the clonidine group than control (beta coefficient (95% CI): 0.18 (0.03, 0.32); p = 0.02 and beta coefficient (95% CI): 1.38 (0.24, 2.52); p = 0.02, respectively). No statistical differences were observed in any of the other secondary outcomes after adjusting for confounders. CONCLUSION: This study found that patients who received clonidine had better functional outcomes during their ICU stay, as shown by their delta GCS than those who did not. Other outcomes were similar between the groups. More data are needed to explore the role of clonidine in patients with TBI with suspected PSH. SAGE Publications 2023-11-07 /pmc/articles/PMC10631352/ /pubmed/37933150 http://dx.doi.org/10.1177/00368504231201298 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Medicine & Health Sciences
Alshaya, Abdulrahman I
Aldhaeefi, Mohammed
Alodhaiyan, Nada
Alqahtani, Maha
Althewaibi, Sarah
Alshahrani, Wala
Al Sulaiman, Khalid
Al Harbi, Shmeylan A.
Vishwakarma, Ramesh
Aldabbagh, Tariq
Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study
title Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study
title_full Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study
title_fullStr Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study
title_full_unstemmed Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study
title_short Clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: A retrospective cohort study
title_sort clonidine safety and effectiveness in the management of suspected paroxysmal sympathetic hyperactivity post-traumatic brain injury: a retrospective cohort study
topic Medicine & Health Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631352/
https://www.ncbi.nlm.nih.gov/pubmed/37933150
http://dx.doi.org/10.1177/00368504231201298
work_keys_str_mv AT alshayaabdulrahmani clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT aldhaeefimohammed clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT alodhaiyannada clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT alqahtanimaha clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT althewaibisarah clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT alshahraniwala clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT alsulaimankhalid clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT alharbishmeylana clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT vishwakarmaramesh clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy
AT aldabbaghtariq clonidinesafetyandeffectivenessinthemanagementofsuspectedparoxysmalsympathetichyperactivityposttraumaticbraininjuryaretrospectivecohortstudy